Arbutus Biopharma Corp  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
Mar 3 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 9.55 - 34.66
Open     -
Vol / Avg. 0.00/31,124.00
Mkt cap 502.11M
P/E     -
Div/yield     -
EPS -2.15
Shares 22.31M
Beta -0.58
Inst. own     -
Mar 10, 2016
Q4 2015 Arbutus Biopharma Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 23, 2016
Arbutus Biopharma Corp at RBC Capital Markets Healthcare Conference Add to calendar
Feb 11, 2016
Arbutus Biopharma Corp at Leerink Partners Global Healthcare Conference
Nov 18, 2015
Arbutus Biopharma Corp at Stifel Healthcare Conference

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -


100-8900 Glenlyon Parkway
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links


Arbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.